Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts

Cancer Research

Volumn 61, Issue 5, 2001, Pages 1799-1804

  Nimmanapalli, R ^a   O'Bryan, E ^a   Bhalla, K ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; BCR ABL PROTEIN; CASPASE 3; CASPASE 9; CHAPERONE; GELDANAMYCIN; GELDANAMYCIN DERIVATIVE; HEAT SHOCK PROTEIN 90; STAT5 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLAST CELL; CANCER RESISTANCE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BENZOQUINONES; CELL DIFFERENTIATION; CYSTEINE ENDOPEPTIDASES; FUSION PROTEINS, BCR-ABL; HEMOGLOBINS; HL-60 CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; K562 CELLS; LACTAMS, MACROCYCLIC; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; QUINONES; RIFABUTIN;

EID: 0035266132     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype
2. Chronic myelogenous leukemia. Biology and therapy
3. S induces differentiation and sensitizes CML-blast crisis K562 cells to ara-C mediated differentiation and apoptosis
4. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3
5. A requirement for NFκB activation in Bcr-Abl-mediated transformation
6. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3K/Akt-dependent pathway
7. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs
8. In vitro eradication of human Bcr/Abl-positive leukemia Cells with an ABL kinase inhibitor
9. Effects of bcr-abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro
10. In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: A novel approach for cancer treatment
11. Oncogene inactivation in a mouse model
12. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides
13. 3 exerts dose-dependent dual effects on APL cells
14. L
15. Molecular chaperones: Biology and prospects for pharmacological intervention
16. The Hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase
17. c-erbB-2c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin
18. A role for Hsp90 in retinoid receptor signal transduction
19. Geldanamycin selectively destabilizes and conformationally alters mutated p53
20. v-src kinase
21. The role of the Hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase
22. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
23. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity
24. The role of Apaf-1, caspase-9, and Bid proteins in etoposide-or paclitaxel-induced mitochondrial events during apoptosis
25. Overexpression of Bcl-xL inhibits ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis
26. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
27. Bcl-xL overexpression inhibits Taxol-induced Yama protease activity and apoptosis
28. The benzoquinone ansamycin 17-allylamino-17demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin
29. Geldanamycin-induced destabilization of Raf-1 involves the proteasome
30. Cellular survival: A play in three Akts
31. Apoptotic pathways: The roads to ruin
32. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells
33. GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression
34. Versatility of Bcr/Abl-expressing leukemic cells in circumventing proapoptotic BAD effects
35. Negative regulation of the Apaf-1 apoptosome by Hsp70
36. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2
37. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome
38. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
39. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias, including chronic myelogenous leukemia in blast crisis
40. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI-571 in BCR/ABL-transformed hematopoietic cell lines
41. Selection and characterization of Bcr-Abl positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
42. Novel anti-Bcr-Abl strategy consisting of arsenic trioxide and CGP57148B lowers Bcr-Abl levels and tyrosine kinase activity resulting in apoptosis and differentiation of Bcr-Abl positive human leukemia cells